<DOC>
	<DOCNO>NCT01790165</DOCNO>
	<brief_summary>The aim study establish clinical bridge Lamisil® tablets conduct clinical pharmacokinetic ( PK ) study compare systemic exposure Lamisil® tablet TDT 067 maximal use condition . Under maximal use condition onychomycotic subject , aim confirm significantly low plasma level terbinafine major metabolite topical administration TDT 067 28 day comparison single oral 250 mg Lamisil® tablet .</brief_summary>
	<brief_title>TDT 067 Open Label Multi-Dose Onychomycosis Study</brief_title>
	<detailed_description />
	<mesh_term>Onychomycosis</mesh_term>
	<mesh_term>Terbinafine</mesh_term>
	<criteria>Subjects must 18 65 year age inclusive , race , either sex . Male subject : Male subject must use reliable form contraception participation trial 3 month last dose study drug . Female subject : Either nonchildbearing potential ( i.e . either surgically sterilize post menopausal ) must use adequate contraception , negative pregnancy test prior start dose , must agree continue use method contraception 3 month last dose . Acceptable contraceptive method oral contraceptive , IUD , diaphragm spermicide ( unless anatomically sterile ) . Subjects must good general health confirm medical history physical examination . Subjects must 2 big toe nail potential clip provide nail sample . Subjects must clinically diagnosed distal subungual onychomycosis toenail ; least 5 nails total must present onychomycotic sign ( onycholysis , subungual hyperkeratosis ) include extensive involvement ( ≥50 % ) large nails mycological confirmation ( positive KOH microscopy ) 1 large nail . Subject must sign statement informed consent . Subjects must able understand requirement study , abide restriction , return require examination Subjects lack toe . Subjects know hypersensitivity terbinafine excipients TDT 067 . Subjects symptomatic tinea pedis require treatment . Subjects medical , neurological , psychiatric condition opinion Investigator would make subject unsuitable enrollment onto study . Subjects chronic active liver disease , well subject elevate liver function test normal test laboratory . Subjects renal impairment ( creatinine clearance ≤50 mL/min ) . Subjects received terbinafine tablet within 12 month topical terbinafine ( cream , solution/spray , gel ) within 6 month prior screen visit ; subject receive oral antifungal within 4 month topical antifungal within 1 month . Subjects participate within previous 3 month clinical trial systemic topical treatment onychomycosis . Subjects treat rifampin cimetidine . Subjects treat investigational drug within 1 month prior study start . Subjects psoriasis history psoriasis . Subjects nail dystrophy nail abnormality onychomycosis . Subjects serious concurrent disease might prevent completion trial . Subjects pregnant ( confirmed pregnancy test ) plan become pregnant within study timeframe nursing . Subjects read , understand , sign inform consent form instruction apply remove study formulation . Subjects apply product toenail . Subjects wish provide nail clipping . Subjects provide adequate blood urine sample . Subjects use nail polish product nail cosmetic product toenails designate treatment within 7 day prior start treatment unwilling discontinue use product duration study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Onychomycosis</keyword>
	<keyword>Open Label</keyword>
	<keyword>PK</keyword>
</DOC>